Hoffmann-La Roche's Prasinezumab Trial Targets Early-Stage Parkinson's Disease
A clinical trial is underway to assess the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease patients.
Asset / Drug
Drug and asset intelligence for Hoffmann-La with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
A new study is underway to evaluate the safety, tolerability, and pharmacokinetics of RO7663498 in diabetic retinopathy patients.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.